As reported in Fierce Biotech, Novartis received more good news from the FDA when it was notified that its MenVeo vaccine had market approval. Analysts predict the Menveo meningitis vaccine could rack up as much as $650 M in sales annually. Even though the vaccine has competition from Sanofi-Aventis' Menactra and Menomune, this new introduction is expected to further expand the market rather than result in a fight for reduced share. MenVeo was approved for use with 11-55 yr old patients. Novartis hopes to expand this to 2-10 yr old populations as well in the future.
Posted by Bruce Lehr Feb 22, 2010